Clinical Trial Detail

NCT ID NCT03701334
Title A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Ribociclib

Age Groups: senior adult

Additional content available in CKB BOOST